A Prospective Observational Study to Assess the Reliability and Validity of the Multi-Luminance Shape Discrimination Test (MLSDT) With 9 Objects

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to ETDRS testing results for the same participants without eGlasses and then with eGlasses. Two cohorts will consist of participants who have vision loss due to STGD or geographic atrophy (GA) due to age-related macular degenerations (AMD). Normally sighted participants will provide a control group.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Males and females, age ≥ 18 years

• Able to comprehend and give informed consent.

• Able to comply with testing and all protocol tests.

• Eligible for 1 of 3 cohorts listed below:

⁃ Cohort 1: Normal-Sighted Participants with clinically normal ocular findings and BCVA range 20/16 to \<20/40 in each eye (ETDRS letter score 71 - 90) Cohort 2: Moderately-Sight Impaired Participants with a BCVA range of 20/40 to \<20/200 (ETDRS letter score of 36 - 70) and a clinical diagnosis of STGD/GA Cohort 3: Severely-Sight Impaired Participants with a BCVA range of 20/200 to 20/800 (ETDRS letter score of 5 - 35) and a clinical diagnosis of advanced STGD/GA

• Clinical diagnosis of STGD for cohorts 2 and 3

• Clinical diagnosis for GA (due to AMD) for cohorts 2 and 3

• Participants who have had anti-VEGF therapy 2 weeks prior to enrollment have to demonstrate 3 months of vision stability and be fluid free on OCT.

Locations
United States
Texas
Retina of North Texas,
RECRUITING
Dallas
Contact Information
Primary
Nozhat Choudry, Ph.D
nchoudry@nanostherapeutics.com
(817) 857-1186
Time Frame
Start Date: 2025-01-28
Estimated Completion Date: 2025-05-27
Participants
Target number of participants: 30
Treatments
Cohort 1:
Normal-Sighted Participants with clinically normal ocular findings and BCVA range 20/16 to \<20/40 (ETDRS letter score 71 - 90) in each eye.
Cohort 2
Moderately Sight-Impaired Participants with a BCVA range of 20/40 to \<20/200 (ETDRS letter score of 36 - 70) and a clinical diagnosis of STGD/GA.
Cohort 3
Severely Sight-Impaired Participants with a BCVA range of 20/200 to 20/800 (ETDRS letter score of 5 - 35) and a clinical diagnosis of advanced STGD/GA.
Sponsors
Leads: Nanoscope Therapeutics Inc.

This content was sourced from clinicaltrials.gov